Irene Perlich - 15 Sep 2023 Form 3 Insider Report for NGM BIOPHARMACEUTICALS INC

Role: Principal Accounting Officer
Signature: /s/ Valerie Pierce, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 15 Sep 2023
Net transactions value: $0
Form type: 3
Filing time: 18 Sep 2023, 17:45:34 UTC
Next filing: 08 Nov 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	NGM	Common Stock						10,000	15 Sep 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NGM	Stock Option (Right to Buy)							15 Sep 2023	Common Stock	50,000	$29.62	Direct	F2
holding	NGM	Stock Option (Right to Buy)							15 Sep 2023	Common Stock	35,000	$15.20	Direct	F3
holding	NGM	Stock Option (Right to Buy)							15 Sep 2023	Common Stock	17,500	$5.36	Direct	F4
holding	NGM	Stock Option (Right to Buy)							15 Sep 2023	Common Stock	30,000	$4.36	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock issuable upon the vesting and settlement of restricted stock units ("RSUs"). 1/4th of the RSUs vest on each of January 15, 2024, January 15, 2025, January 15, 2026 and January 15, 2027.
F2	The shares subject to the option shall vest over a four-year period commencing March 22, 2021, with 1/4th of the shares vesting on March 22, 2022 and 1/48th of the shares vesting monthly thereafter.
F3	The shares subject to the option shall vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
F4	The shares subject to the option shall vest over a two-year period commencing November 4, 2022, with 1/2 of the shares vesting on an annual basis.
F5	The shares subject to the option shall vest over a four-year period commencing January 1, 2023, with 1/48th of the shares vesting on a monthly basis.